Max Hallin
Impact in
- Oncology top 10%
- Cancer-related Molecular Pathways
- Pancreatic and Hepatic Oncology Research
-
- Cancer Genomics and Diagnostics
- Cancer, Hypoxia, and Metabolism
Papers in
-
- Angiogenesis and VEGF in Cancer 2
- Protein Degradation and Inhibitors 1
- Histone Deacetylase Inhibitors Research 1
- Oncology 2
- Pancreatic and Hepatic Oncology Research 1
- Co-authors
- Robert S. Kania (1 shared paper)Shinji Yamazaki (2 shared papers)Jeffrey H. Chen (1 shared paper)Karin Amundson (2 shared papers)David R. Shalinsky (1 shared paper)Michele McTigue (2 shared papers)Maren L. Grazzini (2 shared papers)Dana D. Hu‐Lowe (2 shared papers)
- Journals
- Journal of Clinical Oncology (2 papers)Clinical Cancer Research (2 papers)Journal of Hematology & Oncology (1 paper)Cancer Research (1 paper)
- Partner nations
- United States
In The Last Decade
Max Hallin
6 papers receiving 649 citations
Max Hallin's Hit Papers
Peers
Comparison fields: 5 of 77
- Oncology 230
- Cancer Research 107
- Pulmonary and Respiratory Medicine 217
- Molecular Biology 291
- Genetics 29
Countries citing papers authored by Max Hallin
This map shows the geographic impact of Max Hallin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Max Hallin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Max Hallin more than expected).
Fields of papers citing papers by Max Hallin
This network shows the impact of papers produced by Max Hallin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Max Hallin. The network helps show where Max Hallin may publish in the future.
Co-authors
The 25 scholars most cited alongside Max Hallin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3 Hit paper breakdown → | 2008 | 540 |
| 2 | 2017 | 51 | |
| 3 | 2009 | 48 | |
| 4 | 2021 | 9 | |
| 5 | 2020 | 7 | |
| 6 | PF-00337210, a potent, selective and orally bioavailable small molecule inhibitor of VEGFR-2 | 2007 | 7 |
About Max Hallin
Max Hallin is a scholar working on Molecular Biology, Oncology, Genetics, Pulmonary and Respiratory Medicine and Cell Biology, having authored 6 papers that have together received 662 indexed citations. Recurring topics across this work include Angiogenesis and VEGF in Cancer (2 papers), Chronic Lymphocytic Leukemia Research (1 paper), Pancreatic and Hepatic Oncology Research (1 paper), Renal cell carcinoma treatment (1 paper), Protein Degradation and Inhibitors (1 paper), Histone Deacetylase Inhibitors Research (1 paper), Phagocytosis and Immune Regulation (1 paper) and Microtubule and mitosis dynamics (1 paper). The work is most often cited by research in Oncology (230 citations), Cancer Research (107 citations), Pulmonary and Respiratory Medicine (217 citations), Molecular Biology (291 citations) and Genetics (29 citations). Max Hallin has collaborated with scholars based in United States. Frequent co-authors include Robert S. Kania, Shinji Yamazaki, Jeffrey H. Chen, Karin Amundson, David R. Shalinsky, Michele McTigue, Maren L. Grazzini, Dana D. Hu‐Lowe, Xinglin Wu and Steve Bender. Their work appears in journals such as Journal of Clinical Oncology, Clinical Cancer Research, Journal of Hematology & Oncology and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.